CD4 T cell phenotype after AS01-adjuvanted immunization is shaped by prior antigen or pathogen exposure. [PDF]
van der Most RG, Leroux-Roels G.
europepmc +1 more source
Modeling time-varying efficacy of RTS,S/AS01 malaria vaccine across trial settings. [PDF]
Zhao Z, Milligan P, Cheung YB.
europepmc +1 more source
Malaria Vaccine Rollout in Nigeria: Current Status and Challenges. [PDF]
Oyegbade SA +6 more
europepmc +1 more source
Accessibility, safety, and early effect of the malaria vaccine in routine immunisation practice among children under 36 months in the Soa Health District, Cameroon. [PDF]
Bekolo CE +5 more
europepmc +1 more source
Licensed and investigational TLR4 agonists as vaccine adjuvants: structural basis, clinical progress, and future directions. [PDF]
Zhou J +10 more
europepmc +1 more source
Infection, vaccination and risk of dementia: a proposed immunological model. [PDF]
Devine J +4 more
europepmc +1 more source
Timing of the fourth dose of RTS,S/AS01 malaria vaccine in perennial settings: a modelling study. [PDF]
Figueroa-Downing D +4 more
europepmc +1 more source
Who will pay for the malaria vaccines in Africa? [PDF]
Musa SS +4 more
europepmc +1 more source
Reply to: Methodological Issues in Taquet et al.'s analysis preclude any conclusions regarding AS01 adjuvant's specific role in dementia prevention. [PDF]
Taquet M, Todd JA, Harrison PJ.
europepmc +1 more source
Assessing the potential impact of the RTS,S/ASO1 vaccine on malaria burden in Benin: a mathematical modelling approach. [PDF]
Gbaguidi GJ +8 more
europepmc +1 more source

